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1. Introduction 
Acute kidney injury (AKI), previously termed acute renal failure, is a frequent clinical 
condition in critically ill patients, especially in intensive care units (ICU). It is characterized 
by a rapid decline or loss of renal function. Its incidence varies from 1-7 % of all hospitalized 
patients to 30-50 % of patients in ICU [29,69]. Clinical manifestations include a rapid 
decrease (oliguria) or cessation (anuria) of urine output and of glomerular filtration rate 
(GFR) below 10 mL/min within hours to days. AKI is further indicated by accumulation of 
nitrogenous-waste substances in blood resulting in elevated serum levels of creatinine and 
blood urea nitrogen (BUN). It is important to differentiate AKI from chronic kidney disease 
(CKD), as AKI has the potential to be reversible. AKI and CKD can be differentiated by the 
dynamics nitrogenous-waste substances increase in the serum and urinary output decreases.  
Irrespective of the progress being made in the understanding of the pathophysiology of AKI 
and its underlying processes and the advances in critical care medicine, mortality rate 
associated with AKI remains high especially in ICU patients at more than 50 % [97]. In 
addition, a significant proportion of surviving patients (20 %) develops CKD and end-stage 
renal disease, requiring chronic renal replacement therapy [8,32]. Long-term outcome is 
worse for patients after recovery from AKI [45,14], further impacting health care cost and 
quality of life [10].  
Advances in our understanding, prevention and treatment of AKI have been hampered 
especially by two factors. Firstly, until recently there was a lack of uniform criteria for 
definition and classification of AKI. Secondly, there is still an incomplete understanding of 
the pathogenesis of AKI [72]. The risk to develop AKI is determined by patient’s 
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susceptibility and exposure or causative factors. Patient susceptibility in developing 
countries varies from that of the developed countries. In developing countries, AKI is more 
common in young and pediatric patients, while in developed countries elderly patients are 
predominant [95,34]. However, it is difficult to differentiate demographic variables which 
directly contribute to the risk of developing AKI from those that are more attributed to the 
underlying disease [72]. Conditions known to cause AKI in susceptible populations include 
sepsis, ischemia, heart failure, liver disease, major surgery (especially vascular and cardiac), 
rhabdomyolysis, urinary tract obstruction and various nephrotoxic drugs and radiocontrast 
agents [80].  In critically ill patients the most common cause of AKI is sepsis, accounting for 
50 % of all cases [2,4,5]. 
2. Diagnostic problem 
In order to standardize and detect AKI, two different sets of definition criteria have been 
recently established. The Acute Dialysis Quality Initiative developed the RIFLE criteria for 
the diagnosis of acute renal failure in critically ill patients [6] and the Acute Kidney Injury 
Network developed the AKIN criteria for the diagnosis of AKI [51]. Both criteria (Figure 1) 
for diagnosis are mainly based on measurements of urine output and serum creatinine. In 
clinical practice, however, AKI is predominantly detected by changes in serum creatinine [51].  
 
Fig. 1. AKI staging according to the RIFLE and AKIN criteria. 
Creatinine is a 113 Dalton molecule derived from creatine metabolism after creatinine’s 
release from the muscle. As creatinine is freely filtered by the glomerulus and excreted 
without significant metabolic changes or reabsorption by the kidney, this molecule has been 
< 0.3 mL/kg/h for > 24 h or anuria for > 12 h> 300 % or dialysis3
< 0.5 mL/kg/h for > 12 h201 – 300 %2
< 0.5 mL/kg/h within 6 – 12 h≥ 0.3 mg/dL or 150 – 200 %1
Urine output ↓Serum creatinine ↑Stage
AKIN criteria (Mehta et al., Crit Care 2007, [51])
< 0.3 mL/kg/h for 24 h or anuria for 12 h300 % or ≥ 4 mg/dL or > 75 % Failure
Persistent AKI = Complete loss of renal funktion > 4 wkLoss
End-stage renal disease = Complete loss of renal function > 3 moESRD
< 0.5 mL/kg/h for 12 h200 % or > 50 – 75 %Injury
< 0.5 mL/kg/h for 6 h150 % or > 25 – 50 %Risk
Urine output ↓Serum creatinine ↑ or GFR ↓Stage
RIFLE criteria (Bellomo et al., Crit Care 2004, [6])
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a useful indicator of kidney function. However, serum creatinine has important limitations 
as a tool for assessing GFR. Firstly, creatinine levels are affected by a variety of non-renal 
factors such as age, gender, muscle mass, diet and nutritional status [76]. Although 
equations have been developed to correct for some of these factors, these are only applicable 
for CKD but not for AKI as they require stable creatinine metabolism [41]. Secondly, serum 
creatinine concentration and its value is influenced by its volume of distribution that can be 
substantially affected by volume overload, a common situation in AKI [75]. Finally, and 
probably most importantly, serum creatinine increases only after substantial loss of GFR 
resulting in a lag phase in the temporal relationship between serum creatinine increase and 
loss of GFR. As a result, current clinical diagnosis of AKI based on creatinine limits its early 
detection in clinical routine as well as the early implementation of preventive measures. 
Therefore, the development of new AKI biomarkers have had high priority in the 
nephrological community during the last years with the aim to identify markers that are 
superior to serum creatinine in the early detection of AKI. In the following part we will 
shortly summarise the most promising single biomarkers for AKI.  
3. Single biomarkers for AKI 
New biomarkers for AKI can be categorized as inflammatory mediators, excreted tubular 
proteins and surrogate markers indicative for tubular damage (albumin, α 1-microglobulin, 
β 2-glycoprotein, plasma retinol binding protein, N-acetyl-β-D-glucosaminidase (NAG)) and 
liver-type fatty acid binding protein (L-FABP) [90,18]. The most promising of the AKI 
biomarker candidates, namely neutrophil gelatinase-associated lipocalin (NGAL), kidney 
injury molecule-1 (KIM-1), interleukin-18 (IL-18) and cystatin C (CysC) will be presented in 
more detail:  
3.1 Neutrophil gelatinase-associated lipocalin (NGAL) 
Function: NGAL, also known as lipocalin-2, is a 25-kDa protein strongly up-regulated by 
interleukin-1 during inflammation. NGAL has the ability of sequestering siderophores, 
microbial iron-chelating agents required for bacterial growth, and prevents urinary tract 
infection. 
Diagnostic evidence: NGAL has been presented as biomarker for early detection of AKI and 
for AKI prognosis [68]. The first study that pointed out the association of NGAL with AKI 
development was performed by Mishra and colleagues in 2005 [55]. In this prospective 
study urine and plasma NGAL rose significantly in children developing AKI after cardiac 
surgery within 2 h postoperatively. However, the classification performance of NGAL 
decreased in similar studies performed in adults also having cardiac surgery [21] possibly 
due to confounding variables and comorbid conditions that accumulate with age. Other 
positive results have been obtained when NGAL has been tested as a biomarker of AKI in 
kidney transplantation and the subsequent development of delayed graft function [56]. 
Among other, NGAL was tested in hemolytic uremic syndrome [78], urinary tract infections 
[96], critically ill children and adults [91,70] and also CKD [20]. Taken together, NGAL is the 
most promising novel renal biomarker in urine and also in plasma. However, as pointed out 
by Chawla and Kellum [9], NGAL is expressed in multiple organs affording further studies 
to understand how non-kidney sources of NGAL have an impact on urinary NGAL. As a 
consequence, prospective multicenter studies are urgently required to determine the 
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performance of plasma and urinary NGAL in unselected ICU patient populations including 
patients with preexisting CKD [53,50]. Since the reported cut-off values for NGAL differ 
across a wide range it seems reasonable to speculate, that each clinical setting may require 
different cut-off values [57].  
3.2 Interleukin-18 (IL-18) 
Function: IL-18 is an 18-kDa proinflammatory cytokine secreted by macrophages and other 
antigen presenting cells. It has the ability to induce interferon γ production in type-1 T 
helper cells and is a sensitive mediator of ischemic injury in different organs such as heart, 
brain and kidney [73]. 
Diagnostic evidence: A first evidence for IL-18’s role in ischemic AKI was given by animal 
studies [52,26]. Later studies in humans suggested that urinary IL-18 may serve as marker of 
AKI development after cardiac surgery, of graft function after kidney allograft 
transplantation, and of mortality in acute respiratory distress syndrome [61,62,89]. Siew et 
al. [71] reported that urinary IL-18, when measured within 48 h of AKI development, could 
not reliably predict AKI in a broadly selected, critically ill adult patients cohort. Despite this 
negative result, urinary IL-18 remained predictive in this study for worse clinical outcome 
such as death and acute dialysis within 28 days of ascertainment independently of other 
factors [71]. A matter of concern is that IL-18 increases in a variety of pathophysiological 
conditions, such as sepsis, inflammatory arthritis, inflammatory bowel disease, systemic 
lupus erythematosus, psoriasis, hepatitis and multiple sclerosis. This property significantly 
limits its application, due to reduced sensitivity and specificity [81]. 
3.3 Kidney injury molecule-1 (KIM-1) 
Function: KIM-1 is a type 1 transmembrane glycoprotein that is undetectable in normal 
kidneys but highly expressed by proximal tubules epithelial cells after ischemic or toxic 
injury [31,25] with the ectodomain being shedded into the tubular lumen [100]. It functions 
as a phosphatidyl-serine receptor and confers a phagocytic phenotype on epithelial cells, 
most likely to clear cellular debris during enhanced apoptosis [30].  
Diagnostic evidence: In previous studies in adults, KIM-1 was able to discriminate patients 
with acute tubular necrosis from those without, and predicted AKI in adults undergoing 
cardiac surgery [24,82,87]. In another prospective study on 201 hospital patients with AKI, 
an increase of urinary KIM-1 was associated with increased mortality or dialysis 
requirement [44]. Its potential use as an early marker is based so far on limited data: a rise in 
its urinary levels was detectable before the increase of BUN and creatinine in plasma during 
cadmium-induced renal damage [64] as well as its expression in biopsy sections of kidney 
allograft recipients before histological signs of acute tubular necrosis became evident [99]. 
3.4 Cystatin C (CysC) 
Function: CysC is a cysteine protease inhibitor that is synthesized and continuously released 
into the blood by nucleated cells. Its levels are not significantly affected by age, gender, 
infection, liver disease or muscle mass in contrast to serum creatinine. This molecule is 
freely filtered by the glomerulus but, unlike creatinine, reabsorbed and metabolized by the 
www.intechopen.com
 
Proteomic Biomarkers for the Early Detection of Acute Kidney Injury 
 
109 
proximal tubule. Therefore, elevated levels of CysC in serum correlate inversely with GFR 
while increased urinary CysC indicates renal tubular damage [40] and in fact the diagnostic 
accuracy of serum CysC to reflect GFR has been shown to be superior compared to serum 
creatinine since its levels are less influenced by inflammation, infection, body mass, diet and 
drugs [65].  
Diagnostic evidence: Serum CysC is not a biomarker of AKI since its levels are not a direct 
marker of renal injury, and rather serves as GFR marker [73]. Several studies have focused 
on the diagnostic accuracy of CysC in predicting AKI. Unfortunately, results have been 
conflicting. In high-risk patients serum CysC detected AKI 1-2 days earlier than serum 
creatinine [27]. However, in a mixed heterogeneous, multicenter ICU population serum and 
urinary CysC were poor predictors of AKI and the need for renal replacement therapy [66]. 
In a meta-analysis performed by Zhang et al. [101] using the data of 19 studies from 11 
countries and 3,336 patients, it was found that serum CysC could be used as reliable marker 
with an odds ratio of 23.5 in the prediction of AKI whereas urinary CysC showed only 
moderate diagnostic accuracy with an odds ratio of only 2.6.  
Endre et al. [17] in a recent prospective observational study of 529 ICU patients and Lameire 
et al. [38] in a commentary on this work came to a sobering conclusion on the diagnostic and 
prognostic performance of these single AKI markers. In the study of Endre et al. [17] none of 
these markers reached an AUC value above 0.7 for the prediction of AKI on ICU entry and 
of death in 7 days, while urinary NGAL, CysC and IL-18 predicted dialysis in 7 days with 
AUC’s of 0.79, 0.71 and 0.73, respectively. This is in contrast to some previous studies with 
AUC values above 0.9 [47,55] which was attributed by their selection of homogeneous study 
populations [38]. In conclusion, the single AKI markers performed well in selected, 
predominantly homogenous patient cohorts, whereas they failed for the most part in 
multicenter, heterogenous cohorts which rather represent clinical routine (see Table 1 for a 
listing of clinical studies). Due to this, multimarker patterns were suggested by experts in 
this field for which proteomic technologies are predestined. 
4. Proteomic approaches and biomarkers profiles for AKI 
The main rationale for the application of proteome analysis in the context of AKI is that AKI 
is a multifactorial and heterogeneous process. Due to the diversity of pathological processes 
leading to AKI, it is highly unlikely that one single diagnostic marker may serve as reliable 
predictor for all AKI forms. A broadly applicable, multimarker diagnostic model will avoid 
this. The advantage of such a multimarker strategy is that it allows compensation for 
potential biological, pre-analytical and analytical variances of single biomarkers. 
Mass spectrometry combined with chromatographic separation techniques has advanced 
exceptionally in recent years and has become a valuable tool for profiling of human 
proteomes and a systematic search of protein and peptide markers indicative for various 
renal and non-renal diseases without the need for a hypothesis-driven propagation process 
[54,19,1,93].  
While proteome analysis aiming at biomarkers for renal disease can be focused on urine, 
plasma, or serum, urine seems to be the most attractive body fluid for several reasons. 
Firstly, urine can be obtained in large quantities in a non-invasive manner. Secondly, the 
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Reference Marker Clinical setting 
No. of patients/ 
AKI cases 
AUC 
Koyner et al., 2008 [35] uCysC Post-cardiac surgery 72/34 0.724 
Liangos et al., 2009 [42] uCysC CPB 103/13 0.50 
Koyner et al., 2010 [36] uCysC Post-cardiac surgery 123/46 0.72 
Royakkers et al., 2011 [66] uCysC Mixed ICU 151/91 0.72 
Endre et al., 2011 [17] uCysC/uCr Mixed ICU 529/229 0.67 
Endre et al., 2011 [17] uCysC/uCr Mixed ICU with eGFR <60 ml/min 24/3 0.69 
Endre et al., 2011 [17] uCysC/uCr Mixed ICU with eGFR <60 ml/min 12/8 0.88 
Endre et al., 2011 [17] uCysC/uCr Mixed ICU with eGFR ≥60 ml/min 153/34 0.68 
Endre et al., 2011 [17] uCysC/uCr Mixed ICU with eGFR ≥60 ml/min 104/41 0.77 
Wald et al., 2010 [88] pCysC CPB 150/47 0.68 
Nejat et al., 2010 [58] pCysC Mixed ICU 444/198 0.80 
Herget-Rosenthal et al., 2004 
[27] 
sCysC Mixed ICU 85/44 0.82 
Herget-Rosenthal et al., 2004 
[27] 
sCysC Mixed ICU 85/44 0.97 
Haase-Fielitz et al., 2009 [23] sCysC Post-cardiac surgery 100/23 0.83 
Haase et al., 2009 [22] sCysC Post-cardiac surgery 100/46 0.76 
Chung et al., 2010 [11] sCysC Liver cirrhosis 53/9 0.735 
Krawczeski et al., 2010 [37] sCysC CPB-children 374/119 0.81 
Soto et al., 2010 [74] sCysC Nonsurgical ED 616/130 0.87 
Mishra et al., 2005 [55] uNGAL CPB-children 71/20 0.998 
Zappitelli et al., 2007 [97] uNGAL Mixed ICU - children 140/106 0.78 
Koyner et al., 2008 [35] uNGAL Post-cardiac surgery 72/34 0.705 
Xin et al., 2008 [93] uNGAL Post-cardiac surgery 33/9 0.883 
Wagener et al., 2008 [85] uNGAL Post-cardiac surgery 426/80 0.603 
Bennett et al., 2008 [7] uNGAL CPB 196/99 0.95 
Liangos et al., 2009 [42] uNGAL CPB 103/13 0.50 
Tuladhar et al., 2009 [79] uNGAL CPB 50/9 0.96 
Makris et al., 2009 [47] uNGAL Multi-trauma patients in ICU 31/11 0.977 
Siew et al., 2009 [70] uNGAL Mixed ICU 451/86 0.64 
Han et al., 2009 [24] uNGAL Post-cardiac surgery 90/36 0.59 
Han et al., 2009 [24] 
uNGAL, NAG 
& uKIM-1 
Post-cardiac surgery 90/36 0.75 
w
w
w
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Reference  Marker  Clinical setting  
No. of patients/ 
AKI cases 
AUC 
Koyner et al., 2010 [36] uNGAL Post-cardiac surgery 123/46 0.72 
McIlroy et al., 2010 [50] uNGAL 
Post-cardiac surgery, pre-op. eGFR 60-
90 ml/min 
142/35 0.66 
McIlroy et al., 2010 [50] uNGAL 
Post-cardiac surgery, pre-op. eGFR 90-
120 ml/min 
109/13 0.88 
Metzger et al., 2010 [53] uNGAL Mixed ICU 30/16 0.54 
Wagener et al., 2011 [86] uNGAL/uCr Liver transplantation 92/37 0.8 
Doi et al., 2011 [16] uNGAL Mixed ICU 339/131 0.70 
Endre et al., 2011 [17] uNGAL/uCr Mixed ICU 529/229 0.66 
Endre et al., 2011 [17] uNGAL/uCr Mixed ICU with eGFR <60 ml/min 12/8 0.85 
Endre et al., 2011 [17] uNGAL/uCr Mixed ICU with eGFR ≥60  ml/min 153/34 0.68 
Endre et al., 2011 [17] uNGAL/uCr Mixed ICU with eGFR ≥60  ml/min 83/17 0.69 
Endre et al., 2011 [17] uNGAL/uCr Mixed ICU with eGFR ≥60  ml/min 104/41 0.71 
Haase et al., 2009 [22] pNGAL Post-cardiac surgery 100/46 0.77 
Haase-Fielitz et al., 2009 [23] pNGAL Post-cardiac surgery 100/23 0.8 
Tuladhar et al., 2009 [79] pNGAL CPB 50/9 0.80 
Cruz et al., 2010 [13] pNGAL Mixed ICU 301/133 0.78 
Constantin et al., 2010 [12] pNGAL Mixed ICU 88/52 0.92 
Wheeler et al., 2008 [91] sNGAL 
children with SIRS or septic shock in 
ICU 
143/22 0.677 
Koyner et al., 2008 [36] uKIM-1 Post-cardiac surgery 123/46 0.67 
Han et al., 2009 [24] uKIM-1 Post-cardiac surgery 90/36 0.68 
Liangos et al., 2009 [42] uKIM-1 CPB 103/13 0.78 
Metzger et al., 2010 [53] uKIM-1 Mixed ICU 30/16 0.71 
Endre et al., 2011 [17] uKIM-1/uCr Mixed ICU 529/229 0.66 
Endre et al., 2011 [17] uKIM-1/uCr Mixed ICU with eGFR <60 ml/min 24/3 0.73 
Endre et al., 2011 [17] uKIM-1/uCr Mixed ICU with eGFR ≥60  ml/min 83/17 0.72 
Endre et al., 2011 [17] uKIM-1/uCr Mixed ICU with eGFR ≥60  ml/min 104/41 0.66 
Parikh et al., 2006 [62] uIL-18 CPB-children 71/20 0.75 
Xin et al., 2008 [93] uIL-18 Post-cardiac surgery 33/9 0.894 
w
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Reference  Marker  Clinical setting            
No. of patients/ 
AKI cases 
Liangos et al., 2009 [42] uIL-18 CPB 103/13 
Metzger et al., 2010 [53] uIL-18 Mixed ICU 30/16 
Siew et al., 2010 [71] uIL-18 Mixed ICU 451/86 
Doi et al., 2011 [16] uIL-18 Mixed ICU 339/131 
Endre et al., 2011 [17] uIL-18/uCr Mixed ICU 529/229 
Endre et al., 2011 [17] uIL-18/uCr 
Mixed ICU with eGFR <60 
ml/min 
12/8 0.94
Endre et al., 2011 [17] uIL-18/uCr 
Mixed ICU with eGFR ≥60 
 ml/min 
83/17 0.72
Liangos et al., 2009 [43] pIL-8 CPB 143/59 
Han et al., 2009 [24] uNAG Post-cardiac surgery 90/36 
Liangos et al., 2009 [42] uNAG CPB 103/13 
Doi et al., 2011 [16] uNAG Mixed ICU 339/131 
Portilla et al., 2007 [63] uL-FABP 
Post-cardiac surgery - 
children 
40/21 
Doi et al., 2011 [16] uL-FABP Mixed ICU 339/131 
Matsui et al., 2012 [49] uL-FABP Post-cardiac surgery 85/48 
Katagiri et al., 2012 [33] 
uL-FABP & 
uNAG 
CPB 77/28 
w
w
w
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urinary proteome is relative stable since it is retained in the bladder for several hours, 
providing sufficient time for complete proteolytic processing by endogenous proteases. The 
low molecular weight proteome of the urine does not undergo any significant change if 
urine is stored for up to 3 days at 4°C or 6 h at room temperature [67,77].  
For these reasons, several groups have embraced the search for urinary proteomic 
biomarkers for the early detection of AKI using different analytical platforms. In an early 
study conducted in 2005, Nguyen et al. [59] identified 4 proteins with a mass-to-charge ratio 
(m/z) of 6.4, 28.5, 43 and 66 kDa, being increased at baseline and at 2 and 6 h post-operation 
in the urine of children that developed ischemic kidney injury 2-3 days after 
cardiopulmonary bypass (CPB). These proteins in combination allowed detection of AKI in 
this small patient cohort with 100 % sensitivity and specificity. One of these proteins (m/z 
6.4) was later identified as aprotinin [60], a very basic polypeptide with serine protease 
inhibitory activity, negatively affecting both coagulation and fibrinolysis [48]. The other 3 
peaks were identified as acute-phase proteins α 1-microglobulin (28.5 kDa), α 1-acid 
glycoprotein (43 kDa) and albumin (66 kDa) [15]. 
Using the same analytical platform Ho and colleagues identified, besides known up-
regulated tubular injury markers, two novel peptide peaks at 2.43 and 2.78 kDa that were 
significantly increased in patients after CPB surgery not developing AKI [28]. The authors 
were able to resolve one of these peptides as hepcidin-25, the active form of hepcidin, which is 
secreted by the liver to maintain iron homeostasis and which is up-regulated during acute phase 
response [83].  
Metzger et al. [53] used capillary electrophoresis mass spectrometry to identify urinary 
peptide markers predictive for AKI in urine samples obtained from ICU patients who later 
developed AKI defined by a serum creatinine increase ≥ 50 % in ≤ 48 hours (maximum 5 
days prior AKI) or remained normal in kidney function. The 20 statistically most significant 
peptide markers in a comparative group analysis (Figure 2) were combined to a support 
vector machine-based classifier, which allowed classification of a blinded test set of ICU 
patient samples (n=20, 9 case and 11 controls) with 89 % sensitivity and 82 % specificity. In 
order to evaluate general applicability, this classifier was further applied to the classification 
of urine samples from hematopoietic stem cell transplanted patients of whom 13 developed 
AKI after transplantation and 16 did not. AUC in this validation set was 0.90 with sensitivity 
and specificity values of 94 and 82 %, respectively. The 20 polypeptides were identified by 
amino acid sequencing as degradation products of 6 proteins. Fragments of albumin, α 1-
antitrypsin and β 2-microglobulin were up-regulated, fibrinogen α chain, collagen 1 α(I) and 
collagen 1 α(III) were down-regulated in AKI. The alterations of these polypeptides 
identified in the urine may be attributed to differences in production rates, increased 
assembly into filaments, increased proteolysis in the plasma or urine, abnormal renal 
function, or a combination of the above, and may be relevant at different points of the 
disease process as outlined in figure 3. 
A recent study of Maddens et al. [46] using LTQ-OrbiTRAP for mass spectrometry analysis 
identified urinary NGAL, thioredoxin, gelsolin, chitinase 3-like protein 1 and 3 and acidic 
mammalian chitinase as being the most discriminating markers for experimental sepsis-
induced AKI in mice. Differential expression was verified by immunoblot analysis in urine, 
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plasma and renal tissue homogenates. In a small set of human septic patients the authors 
detected possible differences in excretion levels of the human homologue of chitinase 3-like 
protein 1 and acidic mammalian chitinase protein between patients with compared to those 
without AKI. However, the study was too small to draw any conclusions. The potential use 
of chitinase proteins as sensitive markers for diagnosis of septic-induced AKI is limited, as 
the authors stated, mostly by the fact that increased levels are also detectable during 
inflammatory responses, such as asthma or inflammatory bowel disease, liver fibrosis and 
also for non-AKI patients of the AKI study group without recognizable comorbidities. 
 
Fig. 2. Distribution of urinary peptides included in the AKI-specific biomarker panel of 
Metzger et al., 2010 [53]. AUC’s for ROC comparison of AKI and non-AKI within the ICU 
and HSCT patient groups are shown in the insets. Abbreviations: AKI, acute kidney injury; 
AUC, area under the curve; HSCT, hematopoietic stem cell transplantation; ICU, intensive 
care unit; ROC, receiver operating characteristics. Modified from data shown in Metzger et 
al., 2010 [53]. 
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Gel-based proteomics has also been tested as a platform in the search for biomarkers of AKI. 
Using this methodological approach, Aregger et al [3] identified 3 proteins in a cohort of 36 
patients undergoing CPB to be differentially regulated between patients who developed 
AKI and those who not. The identified proteins were albumin, being upregulated, and zinc 
α 2-glycoprotein and adrenomedullin-binding protein, both down-regulated. Limiting the 
results of the study, only zinc α 2-glycoprotein was applied to a validation set of 22 patients 
with AKI and 46 patients without to test its diagnostic performance in immunoblot and 
ELISA. An AUC value of 0.68 revealed that zinc α 2-glycoprotein is only a weak predictor of 
AKI.    
 
Fig. 3. Pathophysiological relevance of parent proteins from the peptides included in the 
AKI-specific proteomic biomarker model of Metzger et al., 2010 [53]. 
Abbreviations: A1AT, α 1-antitrypsin; ALBU, albumin; B2MG, β 2-microglobulin;  
CO1A1, collagen 1 α(I) chain; CO1A3, collagen 1 α(III) chain; ECM, extracellular matrix;  
FIBA, fibrinogen α chain; MMP, matrix metallopeptidases. 
5. Conclusion 
It is evident that an effective prevention or intervention strategy for patients particularly 
in the ICU (with the possible therapeutic options depicted in figure 4) relies on accurate 
and early detection of AKI. Considering the heterogeneity and complexity of AKI, a 
multiple marker approach seems to be more favourable over single markers. A 
multimarker approach will not rely on particular, single aspects of AKI, i.e. tubular 
damage, fibrosis, inflammation, necrosis or apoptosis, but combine the significant 
findings indicative of specific etiologies, ideally enabling detection of AKI independent of 
the underlying cause.  
Irrespective of the approach, large, prospective, multicentre clinical trials on unselected 
patient populations are required to validate the different proposed biomarkers or classifiers. 
In analogy to a recent editorial by Vlahou [84], such a large study would best be performed 
in a way that allows testing all the biomarkers currently proposed. Unfortunately, neither 
industry, nor government agencies currently see the need for such a large trial.  
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Once suitable biomarkers and classifiers for accurate, early detection of AKI have been 
identified, it is essential to design an easy-to-apply analytical test based on these markers 
that is suitable for routine laboratory use ideally as a point of care device in intensive care 
units. One promising approach is the application of MALDI-MS as a robust and fast 
platform for efficient analysis of urinary biomarkers, which has been demonstrated feasible 
in CKD [39]. 
 
Fig. 4. Intervention aiming at AKI prevention. 
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